Get the Stockscreener App
1.63
5.23%
-0.09
After Hours:
1.64
0.01
+0.61%
Soligenix Inc stock is traded at $1.63, with a volume of 587.96K.
It is down -5.23% in the last 24 hours and down -44.18% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.72
Open:
$1.72
24h Volume:
587.96K
Relative Volume:
0.06
Market Cap:
$6.99M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.2156
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
-0.61%
1M Performance:
-44.18%
6M Performance:
-16.84%
1Y Performance:
-53.69%
1-Day Range:
$1.59
$1.73
1-Week Range:
$1.55
$1.97
52-Week Range:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.63 | 14.40M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Understanding Soligenix Inc.’s price movementM&A Rumor & Safe Investment Capital Preservation Plans - newser.com
Soligenix (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL - Digital Journal
Soligenix Updates Medical Advisory Board to Advance Phase 3 Development of HyBryte for Cutaneous T-Cell Lymphoma – citybuzz - citybuzz
Soligenix updates medical advisory board for lymphoma treatment - Investing.com
Soligenix updates medical advisory board for lymphoma treatment By Investing.com - Investing.com Canada
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire
Why Soligenix Inc. stock could outperform in 2025Weekly Profit Report & Fast Gain Stock Tips - newser.com
Soligenix Secures $7.5 Million in Public Offering to Advance Rare Disease Pipeline Through 2026 - citybuzz
What sentiment indicators say about Soligenix Inc. stockQuarterly Investment Review & Real-Time Buy Zone Alerts - newser.com
What machine learning models say about Soligenix Inc.Trade Risk Report & Low Drawdown Trading Techniques - newser.com
Will Soligenix Inc. stock deliver long term returnsMarket Trend Report & Reliable Intraday Trade Alerts - newser.com
Soligenix Inc.’s volatility index tracking explained2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Why analysts raise outlook for Soligenix Inc. (DOA0) stock2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Soligenix (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL - The Globe and Mail
Is Soligenix Inc. (DOA) stock overpriced at current multiplesWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
Soligenix Inc. stock retracement – recovery analysisJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Applying chart zones and confluence areas to Soligenix Inc.Portfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Soligenix Expands European Advisory Board to Advance CTCL Treatment Development - citybuzz
Does Soligenix Inc. show high probability of reboundShare Buyback & Growth Focused Stock Pick Reports - newser.com
Will Soligenix Inc. stock recover after recent dropJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
How to manage a losing position in Soligenix Inc.July 2025 Momentum & Short-Term High Return Strategies - newser.com
Soligenix (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL - Digital Journal
Biotech and Medical Tech Stocks to WatchBig Moves Following Clinical Trial News - Investorideas.com
Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates - MarketScreener
EV PD-L1 Decreases in 3 Patients: Aethlon Medical Hemopurifier Shows Early EV, miRNA and T‑cell Changes - Stock Titan
Soligenix Reports Positive Safety Review in Phase 3 CTCL Treatment Trial - citybuzz
Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone - Quiver Quantitative
Soligenix’s Strategic Moves: A Bright Future Ahead? - timothysykes.com
Soligenix shares surge after safety milestone in Phase 3 CTCL trial - MSN
Soligenix stock soars after DMC confirms safety in Phase 3 CTCL study - Investing.com
Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safet - GuruFocus
Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial - TipRanks
Soligenix reports safety milestone in phase 3 CTCL treatment trial - Investing.com India
Soligenix achieves important safety milestone in its confirmatory phase 3 Clinical Trial of HyBryte(TM) for the treatment of cutaneous T-cell lymphoma - MarketScreener
Soligenix reports safety milestone in phase 3 CTCL treatment trial By Investing.com - Investing.com Canada
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
What analysts say about Soligenix Inc DOA stockEarnings Per Share Trends & Learn to Pick Stocks in Under 10 Minutes - earlytimes.in
Has Soligenix Inc. formed a bullish divergence2025 Retail Activity & Verified Entry Point Signals - newser.com
Regression analysis insights on Soligenix Inc. performance2025 Trade Ideas & Weekly Momentum Picks - newser.com
Should you hold or exit Soligenix Inc. nowBear Alert & Verified Swing Trading Watchlists - newser.com
Using AI based signals to follow Soligenix Inc.Weekly Stock Summary & Consistent Income Trade Recommendations - newser.com
Why Soligenix Inc. (DOA0) stock is trending on social media2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Statistical indicators supporting Soligenix Inc.’s strengthWeekly Stock Report & Low Volatility Stock Recommendations - newser.com
Using economic indicators to assess Soligenix Inc. potentialTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Is Soligenix Inc. (DOA) stock a momentum leaderQuarterly Market Review & Daily Price Action Insights - newser.com
Is Soligenix Inc. stock ready for a breakoutEarnings Growth Summary & Consistent Return Strategy Ideas - newser.com
Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX) - GuruFocus
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):